Liposomal Pemetrexed : Formulation, Characterization and in Vitro Cytotoxicity Studies for Effective Management of Malignant Pleural Mesothelioma

DOI Web Site Web Site PubMed 被引用文献1件 参考文献43件
  • Essam Eldin Noha
    Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University Department of Pharmacokinetics and Biopharmaceutics, Institute of Health Biosciences, The University of Tokushima
  • Elnahas Hanan Mohamed
    Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University
  • Mahdy Mahmoud Abd-Elghany
    Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Zagazig University
  • Ishida Tatsuhiro
    Department of Pharmacokinetics and Biopharmaceutics, Institute of Health Biosciences, The University of Tokushima

書誌事項

タイトル別名
  • Liposomal Pemetrexed: Formulation, Characterization and <i>in Vitro</i> Cytotoxicity Studies for Effective Management of Malignant Pleural Mesothelioma

この論文をさがす

抄録

Pemetrexed (PMX) is a newly developed multi-targeted anti-folate with promising clinical activity in many solid tumors including malignant pleural mesothelioma (MPM). However, PMX does not show sufficient anti-tumor activity in vivo when used alone either due to inefficient delivery of adequate concentrations to tumor tissue or dose-limiting side effects. In order to overcome these problems and to achieve potent anti-tumor activity, PMX was encapsulated into a liposomal delivery system. In the present study, various formulations of liposomal PMX were prepared. The effect of formulation parameters on the encapsulation efficiency of PMX within liposomes was evaluated. In addition, the influence of drug release rate on the in vitro cytotoxicity was investigated. Encapsulation of PMX within liposomes was remarkably increased by the incorporation of cholesterol within liposomal membranes and by increasing the total lipid concentration. Encapsulation efficiency was found to be unaffected by the type of phospholipid used or the inclusion of a cation lipid, DC-6-14. Interestingly, encapsulation of PMX within “fluid” liposomes was found to allow efficient release of PMX from liposomes resulting in a potent in vitro cytotoxicity against MPM MSTO-211H cell line. On the other hand, entrapment of PMX within “solid” liposomes substantially hindered PMX release from liposomes, and thus PMX failed to exert any in vitro cytotoxicity. These results suggest that encapsulation of PMX within “fluid” liposomes might represent a novel strategy to enhance the therapeutic efficacy of PMX while minimizing the side effect encountered by the non selective delivery of free PMX to various body tissues.

収録刊行物

被引用文献 (1)*注記

もっと見る

参考文献 (43)*注記

もっと見る

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ